MARKHAM, ON, Nov. 25 /CNW/ - Cytochroma today announced that Charles W. Bishop, PhD, President and CEO, will be presenting a corporate overview at the 21st Annual Piper Jaffray Health Care Conference. The presentation will take place at 9:10 am EST on Wednesday, December 2, 2009 at the New York Palace Hotel in New York City.
Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company specializes in developing new vitamin D therapies which are designed to safely and effectively treat patients with stage 3, 4 or 5 CKD. Cytochroma has three product candidates in clinical development for CKD patients: CTA018 Injection and CTAP201 Injection are being developed for the treatment of SHPT in stage 5 CKD, while CTAP101 Capsules are being developed for the treatment of vitamin D insufficiency and associated SHPT in stage 3 and 4 CKD. CTA018 Injection is being developed in partnership with Mitsubishi Tanabe Pharma Corporation for the U.S. and Asian markets, and Cytochroma retains co-promotion rights for this product in the U.S. In addition, Cytochroma is developing novel therapies to treat hyperphosphatemia in CKD patients.
For more information about Cytochroma, please visit www.cytochroma.com.
For further information: For further information: Cytochroma Investors: Gordon Ngan, Executive Director, Corporate Development, Tel: (905) 479-5306 ext. 333, firstname.lastname@example.org; Cytochroma Media: Robert Stanislaro (FD), Tel: (212) 850-5657, email@example.com